Yifan Pharmaceutical Co.， Ltd ( Previous name, Yifan Xinfu Pharmaceutical Co., Ltd ) is listed as A-series stock on the Shenzhen Stock Exchange under the security name Yifan Pharm, code 002019.
Yifan is an enterprise that focuses on pharmaceutical innovation and R&D manufacturing. As such, Yifan has established national post-doctorate scientific research center and provincial technical center in China, has acquired a number of high-tech enterprises which employ over one hundred medical-related professionals with masters or doctorate degrees, holds two proprietary technology R&D platforms and has acquired more than 90 international and domestic drug-related patents.
Yifan has achieved several accolades-such as the National Tenth Five-Year PR Project, the National Demonstration of Technology Industrialization Project, the National Torch Program-and was awarded second place for both National Innovation and National Science & Technology Progress.
Guided by its specilaized therapeutic product pipeline , Yifan is devoted to innovation and transformation, focusing activities on key areas like macro molecular biologics, high-value pharmaceuticals and differentiated Traditional Chinese Medicines. Recent and current clinical activities make Yifan the first Chinese enterprise with innovative biologics to enter phase II and phase III clinical trials in the United States leading China's biologics in to US market. Yifan has a robust pipeline of high-value pharmaceutical assets currently under research, of which 10 are in clinical trials, have applications for clinical trials pending or are in production stage. Yifan currently has more than 300 approved drugs across therapeutic areas-such as gynaecology, pediatrics, and dermatology-including more than 30 differentiated Traditional Chinese and Western medicines.
Yifan's key enterprises include a production center for tradtional Chinese medicines and small molecular high-value medicines in Anhui province, a production center for dermatological and gynaecological medicines in Sichuan province, a center for orthopedic medicines and therapeutic infusion solutions in Liaoning province ,a center for R&D and production of macro molecular biologics in Beijing and Shanghai cities, and a center for bulk drugs in Zhejiang province.
Yifan’s pharmaceutical business covers all provinces and municipalities except Hong Kong, Macao and Taiwan. The medicine preparations covers more than 60% in the national second level and above hospitals. Yifan is the largest producer and supplier of vitamin B5 and pro vitamin B5 in the world. The company’s products are sold in countries around the world, and the market share accounts of nearly 40%.
In keeping with the spirit of the motto“industry serves the country”and honouring corporate social responsibility, Yifan is committed to medicine and medical health services, pushing an innovative approach to providing support for and a guarantee to customers, and creating value for society, opportunities for employees, and value for shareholders.